康诺亚-B(02162.HK) 表示,国家药监局已于近日批准司普奇拜单抗(商品名为康悦达)治疗季节性过敏性鼻炎的新适应症上市申请。
司普奇拜单抗已在过往多项临床试验中,显示了良好的安全性及疗效,其治疗成人中重度特应性皮炎的适应症已于2024年9月获批上市,治疗慢性鼻窦炎伴鼻息肉的适应症已于2024年12月获批上市。
(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-07 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.